EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

No Thumbnail Available

Files

PIIS0923753420423671.pdf (106.37 KB)

Date

2020

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

https://www.annalsofoncology.org/article/S0923-7534(20)42367-1/pdf
 http://hdl.handle.net/11727/5789

Collections

Tıp Fakültesi / Faculty of Medicine
Wos Açık Erişimli Yayınlar
Wos İndeksli Yayınlar Koleksiyonu

Endorsement

Review

Supplemented By

Referenced By